APA (7th ed.) Citation

S, G., M, S., I, S., L, P., I, K., M, G., . . . S, D. (2020). Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet (London, England), 396(10262), 1563. https://doi.org/10.1016/S0140-6736(20)32292-3

Chicago Style (17th ed.) Citation

S, Grosicki, et al. "Once-per-week Selinexor, Bortezomib, and Dexamethasone Versus Twice-per-week Bortezomib and Dexamethasone in Patients with Multiple Myeloma (BOSTON): A Randomised, Open-label, Phase 3 Trial." Lancet (London, England) 396, no. 10262 (2020): 1563. https://doi.org/10.1016/S0140-6736(20)32292-3.

MLA (9th ed.) Citation

S, Grosicki, et al. "Once-per-week Selinexor, Bortezomib, and Dexamethasone Versus Twice-per-week Bortezomib and Dexamethasone in Patients with Multiple Myeloma (BOSTON): A Randomised, Open-label, Phase 3 Trial." Lancet (London, England), vol. 396, no. 10262, 2020, p. 1563, https://doi.org/10.1016/S0140-6736(20)32292-3.